trial

Treatment of Psychosis and Agitation in Alzheimer's Disease

NCTId NCT02129348
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 77 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2020-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
77 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2014-06
Primary completion
2020-01
Eligibility
ALL

Interventions & indications

Drugs
Lithium

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute on Aging (NIA)Collaborator

Investigators

1
DP Devanand, MDPrincipal Investigator

Sites

4 total
Miami, United StatesBelmont, United StatesNew York, United StatesDallas, United States

Linked catalysts

1
Treatment of Psychosis and Agitation in Alzheimer's Disease — primary completion2020-01

Facts & assertions

4 sourced
Enrollment
77
Phase
PHASE2
Primary Completion Date
2020-01
Status
COMPLETED
relationships
The graph out of here
drug
Lithium
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute on Aging (NIA)
company
indication
Hallucinations
indication
Psychomotor Agitation
indication
Aggression
indication
investigator
DP Devanand, MD
person